Ann Dermatol.  2015 Oct;27(5):620-621. 10.5021/ad.2015.27.5.620.

Development of Vitiligo during Treatment with Adalimumab: A Plausible or Paradoxical Response?

• Jung JM
• Lee YJ
• Won CH
• Chang SE
• Lee MW
• Choi JH
• Moon KC

• KMID: 2171468
• DOI: http://doi.org/10.5021/ad.2015.27.5.620

Abstract

No abstract available.

MeSH Terms

Vitiligo*
Adalimumab

Figure

• 

  Fig. 1 Multiple well-demarcated irregularly shaped depigmented macules and patches (A) on the left proximal thigh, (B) dorsum of the right foot, (C) dorsum of the right hand, and (D) right forearm.

Reference

1. Exarchou SA, Voulgari PV, Markatseli TE, Zioga A, Drosos AA. Immune-mediated skin lesions in patients treated with anti-tumour necrosis factor alpha inhibitors. Scand J Rheumatol. 2009; 38:328–331.

2. Simón JA, Burgos-Vargas R. Vitiligo improvement in a patient with ankylosing spondylitis treated with infliximab. Dermatology. 2008; 216:234–235.

3. Martínez-Esparza M, Jiménez-Cervantes C, Solano F, Lozano JA, García-Borrón JC. Mechanisms of melanogenesis inhibition by tumor necrosis factor-alpha in B16/F10 mouse melanoma cells. Eur J Biochem. 1998; 255:139–146.

4. Maruthappu T, Leandro M, Morris SD. Deterioration of vitiligo and new onset of halo naevi observed in two patients receiving adalimumab. Dermatol Ther. 2013; 26:370–372.

5. Posada C, Flórez A, Batalla A, Alcázar JJ, Carpio D. Vitiligo during treatment of Crohn's disease with adalimumab: adverse effect or co-occurrence? Case Rep Dermatol. 2011; 3:28–31.